The 10 references in paper V. Dudchenko V., P. Popov I., N. Bunyatyan D., A. Yavorsky N., V. Merkulov A., В. Дудченко В., П. Попов И., Н. Бунятян Д., А. Яворский Н., В. Меркулов А. (2018) “Международные непатентованные наименования биологических и биотехнологических лекарственных средств // International nonproprietary names for biological and biotechnological drugs” / spz:neicon:vedomostincesmp:y:2015:i:4:p:32-38

1
Guidelines on use of International Nonproprietary Names (INNs) for Pharmaceutical Substances. WHO/PHARM S/Nom 1570. Geneva: WHO; 1997.
(check this in PDF content)
2
International Nonproprietary Names: revised procedure. Procedure for the selection of recommended international nonproprietary names for pharmaceutical substances. EB115.R4. Geneva: WHO; 2005.
(check this in PDF content)
3
WHO/EMP/RHT/TSN/2013.1. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. 2013.
(check this in PDF content)
4
WHO International Nonproprietary Names (INN) for Biological and Biotechnological Substances. A Review. Programme on International Nonproprietary Names (INN). Quality Assurance and Safety: Medicines (QSM). Medicines Policy and Standards (PSM) Department.
(check this in PDF content)
5
Vasiliev AN, Gavrishina EV, Niyazov RR, Snegireva AA, Adonin VK. Introduction to the European legislation on medicines. Biological medicines. Remedium 2013; (9): 49–54 (in Russian).
(check this in PDF content)
6
Vasiliev AN, Niyazov RR, Engalycheva GN, Gavrishina EV, Tuter EA, Bekerman AN. Confirmation of the quality, preclinical and clinical studies of similar biological medicinal products. General principles. Remedium 2013; (6): 22–26 (in Russian).
(check this in PDF content)
7
Niyazov RR, Goryachev DV, Gavrishina EV, Romodanovskiy DP, Dranitsyna MA. Justification of the borders of the equivalence of indicators of quality, safety and efficiency in the development of biosimilars. Eksperimentalnaya i klinicheskaya farmakologiya 2015; 78(6): 37–44 (in Russian).
(check this in PDF content)
8
Romanov BK, Glagolev SV, Polivanov VA, Leonova MV. Safety monitoring of medicines. Bezopasnost i risk farmakoterapii 2014; 3(4): 11–14 (in Russian).
(check this in PDF content)
9
Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. U.S. Food and Drug Administration. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm. R E F E R E N C E S Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation, 8 Petrovsky Boulevard, Moscow, 127051, Russian Federation. Dudchenko VV. Leading expert of expertise office of medicines No 1 of Center of expertise and control of finished pharmaceutical products. Candidate of Medical Sciences. Bunyatyan ND. Deputy Di
(check this in PDF content)
10
Васильев АН, Гавришина ЕВ, Ниязов РР, Добровольский АВ, Тутер ЕА, Бекерман АН. Биологически аналогичные лекарственные препараты в Российской Федерации и перспективы их разработки. Ремедиум 2013; (7–8): 67–70. 10. Vasiliev AN, Gavrishina EV, Niyazov RR, Dobrovolskiy AV, Tuter EA, Bekerman
(check this in PDF content)